State Street Corp Boosts Position in Rockwell Medical, Inc. (NASDAQ:RMTI)

State Street Corp grew its position in Rockwell Medical, Inc. (NASDAQ:RMTI) by 21.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 95,004 shares of the company’s stock after buying an additional 16,800 shares during the quarter. State Street Corp owned 0.29% of Rockwell Medical worth $377,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the company. Concurrent Investment Advisors LLC acquired a new stake in shares of Rockwell Medical during the third quarter valued at $40,000. Verus Capital Partners LLC purchased a new position in shares of Rockwell Medical in the 3rd quarter worth $51,000. Beacon Financial Advisory LLC purchased a new position in shares of Rockwell Medical in the 3rd quarter worth $98,000. Renaissance Technologies LLC boosted its holdings in Rockwell Medical by 877.1% in the second quarter. Renaissance Technologies LLC now owns 102,700 shares of the company’s stock valued at $181,000 after acquiring an additional 92,189 shares during the last quarter. Finally, HighTower Advisors LLC grew its position in Rockwell Medical by 75.6% during the third quarter. HighTower Advisors LLC now owns 57,413 shares of the company’s stock valued at $228,000 after acquiring an additional 24,715 shares during the period. Hedge funds and other institutional investors own 23.31% of the company’s stock.

Rockwell Medical Stock Performance

Shares of RMTI opened at $2.33 on Friday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.00 and a current ratio of 2.41. Rockwell Medical, Inc. has a 1 year low of $1.16 and a 1 year high of $5.15. The firm has a fifty day moving average of $2.61 and a 200-day moving average of $2.71. The company has a market cap of $75.30 million, a price-to-earnings ratio of -46.60 and a beta of 1.38.

Analyst Ratings Changes

Several research firms have recently issued reports on RMTI. HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of Rockwell Medical in a research report on Monday, December 23rd. Rodman & Renshaw initiated coverage on Rockwell Medical in a research report on Thursday, November 14th. They issued a “buy” rating and a $5.00 price objective on the stock. StockNews.com downgraded Rockwell Medical from a “buy” rating to a “hold” rating in a research report on Friday, December 20th. Finally, RODMAN&RENSHAW raised Rockwell Medical to a “strong-buy” rating in a research report on Thursday, November 14th.

Rockwell Medical Profile

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.